Dynavax cuts staff in retreat from cancer research
Dynavax cuts staff in retreat from cancer research
Biopharma Dive
Dynavax Technologies
layoffs
restructuring
cancer
R&D
Flag link:
Upcoming events – key tests approach for Biogen and Kalvista
Upcoming events – key tests approach for Biogen and Kalvista
EP Vantage
Biogen
BIIB098
Tecfidera
multiple sclerosis
KalVista
HAE
Biocryst
BCX7353
KVD900
Flag link:
Daiichi Sankyo Denies Report That It's Selling Over-the-Counter Drug Unit
Daiichi Sankyo Denies Report That It's Selling Over-the-Counter Drug Unit
BioSpace
Daiichi Sankyo
OTC
Flag link:
Synlogic (SYBX) Enters Cancer Collaboration with Roche
Synlogic (SYBX) Enters Cancer Collaboration with Roche
Yahoo/Zacks.com
Synlogic
Roche
SYNB1891
Tecentriq
solid tumors
Flag link:
Nektar Therapeutics launches Inheris Biopharma
Nektar Therapeutics launches Inheris Biopharma
Pharmaceutical Business Review
Nektar Therapeutics
Inheris Biopharma
CNS
Flag link:
Novartis’ inhaled asthma combo QVM149 succeeds in two phase 2 trials
Novartis’ inhaled asthma combo QVM149 succeeds in two phase 2 trials
Pharmaceutical Business Review
Novartis
QVM149
clinical trials
asthma
Flag link:
Stoke Therapeutics Files for $86 Million IPO
Stoke Therapeutics Files for $86 Million IPO
CP Wire
Stoke Therapeutics
Dravet syndrome
IPOs
Flag link:
Stoke Therapeutics Files for $86 Million IPO
Stoke Therapeutics
Dravet syndrome
Flag link:
Affimed scraps T-cell engager program, parts company with CSO
Affimed scraps T-cell engager program, parts company with CSO
Fierce Biotech
Affimed
bispecific antibodies
T-cell engager
cancer
Flag link:
India’s Biggest Drugmaker Plans to Start Developing Its Own Medicines
India’s Biggest Drugmaker Plans to Start Developing Its Own Medicines
Bloomberg
generics
India
Sun Pharma
Flag link:
FTC Finds Dwindling Number of Anticompetitive Reverse Payment Deals
FTC Finds Dwindling Number of Anticompetitive Reverse Payment Deals
RAPS.org
FTC
Hatch Waxman Act
anticompetitive practices
Flag link:
5 novel immuno-oncology targets to know before ASCO
5 novel immuno-oncology targets to know before ASCO
Biopharma Dive
immuno-oncology
ASCO 2019
STING
LAG-3
TIM-3
TGF-Beta
OX40
Flag link:
Gene Therapy Company Locana Earns $55 Million in Series A Financing
Gene Therapy Company Locana Earns $55 Million in Series A Financing
BioSpace
Google
Locana
RNA-targeted medicines
Flag link:
A new Senate health package includes surprisingly aggressive drug pricing reforms
A new Senate health package includes surprisingly aggressive drug pricing reforms
Stat
legislation
drug pricing
Flag link:
Study Finds Ketamine Nasal Spray Effective For Treating Depression: What You Should Know
Study Finds Ketamine Nasal Spray Effective For Treating Depression: What You Should Know
Forbes
depression
ketamine
esketamine
Spravato
JNJ
Janssen
Flag link:
Colorado becomes first state to cap out-of-pocket insulin costs
Colorado becomes first state to cap out-of-pocket insulin costs
The Hill
Colorado
insulin
drug pricing
co-pays
diabetes
Flag link:
May 23 2019 - Novartis CEO Narasimhan touts blockbuster pipeline
Flag link:
Novartis chief Vas Narasimhan wants you to know about the '25-plus’ blockbusters he has in the pipeline
Novartis chief Vas Narasimhan wants you to know about the '25-plus’ blockbusters he has in the pipeline
Endpoints
Novartis
R&D
Sandoz
Pharma CEOs
Vas Narasimhan
Flag link:
Eli Lilly’s Generic Insulin Hits Market at Half the Price of Branded Counterpart
Eli Lilly’s Generic Insulin Hits Market at Half the Price of Branded Counterpart
BioSpace
Eli Lilly
drug pricing
generics
insulin
diabetes
Lispro
KwikPens
Flag link:
UPDATED: Sarepta's Exondys 51 is not cost-effective, nor particularly beneficial for DMD patients — ICER
UPDATED: Sarepta's Exondys 51 is not cost-effective, nor particularly beneficial for DMD patients — ICER
Endpoints
Duchenne Muscular Dystrophy
ICER
Sarepta Therapeutics
Exondys 51
Flag link:

Pages